(4S)-4-甲基-2-噁唑烷酮 | 4042-35-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑烷类
• 中文名称: (4S)-4-甲基-2-噁唑烷酮
• 中文别名: (S)-4-甲基噁唑烷-2-酮
• 英文名称: (S)-4-methyloxazolidin-2-one
• 英文别名: (S)-4-methyl-2-oxazolidinone；(4S)-4-methyloxazolidin-2-one；(4S)-(+)-4-Methyl-2-oxazolidinone；(4S)-4-methyl-1,3-oxazolidin-2-one
• CAS: 4042-35-7
• 化学式: C₄H₇NO₂
• 分子量: 101.105
• InChiKey: VAJFEOKPKHIPEN-VKHMYHEASA-N

物化性质

• 熔点：
  52-56 °C
• 沸点：
  302.6±9.0 °C(Predicted)
• 密度：
  1.095±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  7
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2934999090
• WGK Germany：
  3
• 危险性防范说明：
  P280,P305+P351+P338
• 危险性描述：
  H302
• 储存条件：
  储存温度：2-8°C，需干燥密封保存。

SDS

Name:	(4S)-4-Methyl-2-oxazolidinone Material Safety Data Sheet
Synonym:
CAS:	4042-35-7

Section 1 - Chemical Product MSDS Name:(4S)-4-Methyl-2-oxazolidinone Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
4042-35-7	(4S)-4-Methyl-2-oxazolidinone		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 4042-35-7: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white to light yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H7NO2
Molecular Weight: 101.11

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 4042-35-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(4S)-4-Methyl-2-oxazolidinone - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 4042-35-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 4042-35-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 4042-35-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (4S)-4-甲基-2-噁唑烷酮 在 1,1,1,2-四氟乙烷 、 五氧化二氮 作用下， 5.0~20.0 ℃ 、600.01 kPa 条件下， 反应 1.0h， 以87%的产率得到(S)-4-methyl-3-nitrooxazolidin-2-one
  参考文献：
  名称：

  在液化的1,1,1,2-四氟乙烷介质中合成手性N-硝基-恶唑烷-2-酮和O-（β-硝基氨基烷基）氨基甲酸酯

  摘要：

  摘要 通过在液化的1,1,1,2-中与五氧化二氮中的一个或两个立体生成中心的α-氨基酸衍生的1,3-恶唑烷-2-酮进行硝化反应，方便地合成手性N-硝基-恶唑烷-2-酮已经开发了四氟乙烷介质。通过在相同溶剂中用氨或胺处理，将获得的N-硝基杂环转化为对映体纯的O-（β-硝胺氨基烷基）氨基甲酸酯。合成的N-硝基化合物在体外对人胚肾293（HEK293）细胞有轻微毒性。 出版历史 收到：2020年6月2日 修订后接受：2020年7月13日 发布日期： 2020年8月11日（在线） ©2020年。Thieme。版权所有 Georg Thieme Verlag KGRüdigerstraße14，70469斯图加特，德国

  DOI：

  10.1055/s-0040-1706762
• 作为产物：
  描述：

  N-Boc-L-丙氨醇 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 反应 3.08h， 以82%的产率得到(4S)-4-甲基-2-噁唑烷酮
  参考文献：
  名称：

  脑渗透突变IDH1抑制剂临床候选IDH305的发现和评估。

  摘要：

  突变IDH1的抑制作用正在临床上评估为Arg 132处具有热点突变的各种癌症的有前途的治疗选择。确定了IDH1 R132H的变构，诱导口袋后，我们探索了3-嘧啶-4-基-恶唑烷-2-酮作为IDH1突变体抑制剂，用于体内调节2-HG的产生和潜在的脑渗透。我们在这里报告优化工作，以鉴定临床候选者IDH305（13），这是一种有效且选择性的突变体IDH1抑制剂，已在啮齿动物中证明了其对大脑的暴露。该化合物在临床上的临床前表征患者体内IDH1突变异种移植肿瘤模型中2-HG降低与疗效的相关性。IDH305（13）已进入用于治疗具有IDH1突变的癌症的人类临床试验。

  DOI：

  10.1021/acsmedchemlett.7b00342
• 作为试剂：
  描述：

  (4S)-4-甲基-2-噁唑烷酮 、 3-chloro-6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-5-(1,3-dioxolan-2-yl)-7-fluoro-1,2-benzoxazole 在 (4S)-4-甲基-2-噁唑烷酮 作用下， 生成 (4S)-3-{6-[(2R,6S)-2,6-dimethylmorpholin-4-yl]-5-(1,3-dioxolan-2-yl)-7-fluoro-1,2-benzoxazol-3-yl}-4-methyl-1,3-oxazolidin-2-one
  参考文献：
  名称：

  [EN] FUSED, SPIROCYCLIC HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS
  [FR] COMPOSÉS HÉTÉROAROMATIQUES SPIROCYCLIQUES FUSIONNÉS POUR TRAITER LES INFECTIONS BACTÉRIENNES

  摘要：

  本发明涉及式（I）化合物；其药学上可接受的盐，使用它们治疗细菌感染的方法，以及它们的制备方法。

  公开号：

  WO2010043893A1

文献信息

• [EN] 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES<br/>[FR] COMPOSÉS DE 6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE POUR LE TRAITEMENT DE MALADIES INFECTIEUSES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018011160A1

  公开（公告）日：2018-01-18

  The present invention relates to compounds of the formula (I) or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.

  本发明涉及式(I)化合物或药用可接受的盐、对映异构体或非对映异构体，其中R1至R4如上所述。这些化合物可能用于治疗或预防乙型肝炎病毒感染。
• NAPHTHYRIDINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282328A1

  公开（公告）日：2018-10-04

  Naphthyridine compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the naphthyridine compounds.

  萘啶化合物及其作为HPK1抑制剂的用途被描述。这些化合物在治疗HPK1依赖性疾病和增强免疫反应方面很有用。还描述了抑制HPK1的方法、治疗HPK1依赖性疾病的方法、增强免疫反应的方法以及制备萘啶化合物的方法。
• Importance of C−N Bond Rotation in <i>N</i>-Acyl Oxazolidinones in their SmI₂-Promoted Coupling to Acrylamides
  作者：Rolf H. Taaning、Karl B. Lindsay、Birgit Schiøtt、Kim Daasbjerg、Troels Skrydstrup

  DOI：10.1021/ja903401y

  日期：2009.7.29

  correlates with the activation barriers for C-N bond rotation may have implications for other useful synthetic organic reactions involving similar substrates. Finally, these studies were extrapolated to understanding the poor reactivity of N-acyl oxazolidinones, as those derived from Evans chiral auxiliaries, with N-tert-butyl acrylamide. These couplings appear to be dominated by the activation energy for addition

  进行了详细的机理研究，以确定 SmI(2) 促进的 N-酰基恶唑烷酮和丙烯酰胺之间的碳-碳键形成反应中后电子转移步骤的主要因素。通过使两种 N-酰基恶唑烷酮与有限量的 N-叔丁基丙烯酰胺反应来进行竞争实验，然后根据产物分布，计算一系列 N-酰基恶唑烷酮对 N-新戊酰基恶唑烷酮的相对反应性值 (RV)作为参考。当 ln RV 与通过 DFT 计算获得的 CN 键旋转（s-反式到 s-顺式）的激活势垒作图时，对于简单的烷基 N-酰基恶唑烷酮获得了几乎线性的相关性，这意味着 CN 键从 s-trans 到 s-cis 构象的旋转是控制反应性的基本参数之一。这些结果得到了对相应酰亚胺衍生物进行的其他竞争实验的证实，其中旋转对于获得双齿配位是不必要的，并且没有观察到上述的这种相关性。对这些 SmI(2) 介导的转化的简单 N-酰基恶唑烷酮的反应性与 CN 键旋转的激活障碍相关的发现可能对涉及类似底物
• [EN] SUBSTITUTED PYRAZOLO[1,5-a]PYRIMIDINE COMPOUNDS AS mTOR INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLO[1,5-A]PYRIMIDINE SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE MTOR
  申请人：ARRAY BIOPHARMA INC

  公开号：WO2011029027A1

  公开（公告）日：2011-03-10

  Compounds of Formula I: and salts thereof in which R1, R2, R2a, R3, n, X and ring B have the meanings given in the specification, are inhibitors of mTOR and are useful in the treatment of diseases which are sensitive to inhibition of mTOR, such as cancers.

  公式I的化合物：以及其中R1、R2、R2a、R3、n、X和环B具有说明书中给出的含义的盐，是mTOR的抑制剂，可用于治疗对mTOR抑制敏感的疾病，如癌症。
• ISOQUINOLINES AS INHIBITORS OF HPK1
  申请人：Genentech, Inc.

  公开号：US20180282282A1

  公开（公告）日：2018-10-04

  Isoquinoline compounds and their use as inhibitors of HPK1 (hematopoietic kinase 1) are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibitng HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the isoquinoline compounds.

  描述了异喹啉化合物及其作为HPK1（造血激酶1）抑制剂的用途。这些化合物在治疗依赖于HPK1的疾病和增强免疫应答方面非常有用。还描述了抑制HPK1的方法、治疗依赖于HPK1的疾病的方法、增强免疫应答的方法，以及制备异喹啉化合物的方法。